The aims of this study were to evaluate the use of oral fluorescein in capsule form, to determine if there is a dose which will reliably give good quality angiograms, and to discover the best time to photograph the fundus after the capsules have been taken.
fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0.05%). A Fundal photographs were taken with either a Canon CF-60U or Kowa Pro I fundus camera 20, 30, 40 and 60 minutes after the capsules had been swallowed. The film used was Ilford FP4 rated to 800 ASA. The films were developed in Kodak D76 for 30 minutes at 20C.
Results
The 80 angiograms were graded into four categories: 3=strong fluorescence; 2=moderate fluorescence; 1=faint fluorescence; 0=no useful fluorescence.
Grade 3 angiograms were comparable in quality with those produced by intravenous fluorescein. Grade 2 angiograms were also of good quality, and any abnormal leakage would be readily seen. In the grade 1 angiograms the disc and macula could be distinguished and it would be possible to recognise any major leakage. However, small amounts of late leakage might be missed. Grade 0 angiograms did not show any significant degree of fluorescence, and fundal features could not be distinguished. Examples of angiograms from categories 1, 2, and 3 are shown in Figure 1 .
For 15 of the 20 volunteers one or more angiograms in grade 2 or 3 were produced, and 12 of these 15 had one or more grade 3 angiograms. All except one had been given a dose of fluorescein equivalent to at least 25 mg/kg body weight. The best quality angiograms were obtained at 40 or 60 minutes after they had taken the capsules, though good quality angiograms could also be obtained at 30 minutes in some cases. An example of progression offluorescence in successive angiograms is shown in Figure 2 .
For five of the 20 subjects no useful angiograms were obtained. In four of these five there was no visible fluorescence. Although two of the five had been given fluorescein equivalent to less than 15 mg/kg body weight, the other three had received a dose of over 30 mg/kg.
None of the subjects experienced any reaction to the test dose of liquid fluorescein. After taking the capsules one person developed a mild urticarial rash on the extensor surfaces of her arms and legs. She experienced no other ill effects. She was given chlorpheniramine maleate 4 mg by mouth, and the rash resolved over the next four hours.
Discussion
Fluorescein was first synthesised in 1871. It was The incidence of reactions is not easy to establish from the literature. In a prospective study where reactions to IV fluorescein were ascertained by asking each patient to describe any unpleasant sensations, as well as by observation, an incidence of 21% was reported,'8 though all these were mild. In a retrospective study reviewing the records of a number of different institutions in the USA another study found the incidence of reactions to be 0-6%, but of these the majority (66 6%) were severe."
Figures from other studies lie between the two extremes, suggesting that mild reactions are common, occurring in about 20% of injected patients, but that life threatening reactions are rare, occurring in less than 0 05% of patients. This risk factor is nevertheless significant for a procedure which is most commonly undertaken in situations where life is not threatened by the condition being investigated.
There is greater likelihood of a reaction to IV fluorescein in a patient with a history of atopy or drug reactions," but a life threatening reaction, such as acute pulmonary oedema, may occur in a patient who is not atopic and has no respiratory disease. 12 The precise nature of reactions to IV fluorescein is not clear. Some may be due to hypersensitivity (anaphylaxis) as a result of an immunological response of the host to a hapten (drug)-protein combination. Yet the proportion occurring in patients who have received previous injections is not much greater than in patients exposed to fluorescein (in large amounts) for the first time. It is hard to imagine how people who have not been previously injected could become sensitised to fluorescein either through topical applications to their eyes or from the environment. Skin testing with both fluorescein and fluorescein-conjugated human serum albumin (F-HSA) in three patients who had suffered reactions to IV fluorescein yielded only one positive result, and that was to F-HSA."
Raised serum histamine levels have been found after the administration of IV fluorescein to people who have experienced a reaction, but also in a large proportion of those who experienced no ill effects.'8 In spite of the finding of raised levels in unaffected patients, these results do suggest that histamine plays a part in the production of reactions to IV fluorescein. Apart from its role in anaphylaxis, histamine may also be released (in vitro) in the absence ofan antigenantibody reaction. '9 Our results indicate that a dose of 25 mg/kg body weight produces good quality angiograms in 75% of patients. In order to provide comparable results the volunteers for this study were asked to fast before taking the fluorescein, but from earlier experience the authors have found that this is not essential, and for patients with diabetes mellitus it is inadvisable to recommend fasting before oral fluorescein angiography.
In this study the best pictures were obtained by photographing the fundus at 40 and 60 minutes after the capsules had been taken. We recommend the use of oral fluorescein in capsule form when early, high intensity, angiograms are not required, on the grounds of efficiency, convenience, and safety. 
